GlaxoSmithKline PLC
2 January 2002
Directors' Interests
I give below details of a change in the interests in Ordinary Share ADRs of
GlaxoSmithKline plc (each ADR represents two Ordinary Shares) in respect of
the undermentioned Director arising from the purchase of Ordinary Share ADRs
on 20 December 2001 through the quarterly investment element of the US Global
BuyDirect Plan administered by The Bank of New York, which Mr McArthur entered
on 4 May 1997:-
Mr J H Beneficial interest in 142.6683 Ordinary Share ADRs purchased at
McArthur a price of US$ 49.17 per ADR.
Mr McArthur and the Company were advised of this information on 24 December
2001.
S M Bicknell
Company Secretary
2 January 2002
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.